MALIGNANT MELANOMA
Clinical trials for MALIGNANT MELANOMA explained in plain language.
Never miss a new study
Get alerted when new MALIGNANT MELANOMA trials appear
Sign up with your email to follow new studies for MALIGNANT MELANOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo aims to supercharge immune attack on tough melanoma
Disease control OngoingThis early-phase study tests whether adding an oral drug (DEC-C) to the immunotherapy nivolumab can help the immune system better attack mucosal melanoma, a rare and hard-to-treat skin cancer. The trial includes 8 adults with advanced disease that cannot be removed by surgery. Th…
Matched conditions: MALIGNANT MELANOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated May 26, 2026 06:36 UTC
-
New combo attack on brain melanoma: radiation plus drugs show promise
Disease control OngoingThis study tests whether adding a precise type of radiation (stereotactic radiosurgery) to a three-drug combination (binimetinib, encorafenib, and pembrolizumab) can better control melanoma that has spread to the brain in people with a specific BRAF gene mutation. Ten adults with…
Matched conditions: MALIGNANT MELANOMA
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New vaccine combo shows promise in advanced skin cancer trial
Disease control OngoingThis study tests two experimental cancer vaccines, SCIB1 and iSCIB1+, given alongside standard immunotherapy drugs (nivolumab with ipilimumab or pembrolizumab) for people with advanced melanoma that cannot be removed by surgery. The goal is to see if adding the vaccines is safe a…
Matched conditions: MALIGNANT MELANOMA
Phase: PHASE2 • Sponsor: Scancell Ltd • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
New hope for kids with tough melanoma: drug combo shows promise
Disease control OngoingThis study tested a combination of two drugs (temozolomide and peginterferon alfa-2b) in 29 children and teens with advanced or returning melanoma that could not be removed by surgery. The main goal was to see how well the treatment shrank tumors and to check for side effects. Th…
Matched conditions: MALIGNANT MELANOMA
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 20, 2026 11:53 UTC